CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease...
- Mechanism
- Curator reviewed
CTI-01 inhibits the systemic release of cytokines, such as TNF-alpha and HMGB1, which promote the body's inflammatory response. The over-expression of these cytokines has been linked to diseases that occur in critical care settings, such as severe organ damage following cardiopulmonary bypass (CPB) and post-operative ileus following abdominal surgery.
- Primary indication
- Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia.Curator reviewed
- Formula / weight
- C5H8O3 · 116.1152 g/mol (avg)
- Also known as
- Ethyl 2-oxopropanoate · Ethyl 2-oxopropionate · Ethyl methylglyoxylate · Pyruvic acid ethyl ester · Pyruvic acid, ethyl ester
- Code names
- CTI-01 · FEMA NO. 2457 · NSC-48386
Resolves to
XXRCUYVCPSWGCC-UHFFFAOYSA-NSMILESCCOC(=O)C(C)=OWhat you can answer from here — as of June 12, 2020
Which drugs share a target with Ethyl pyruvate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account